Varian reported net earnings of $19.5 million versus $14 million in the same quarter last year. Sales for the quarter totaled $191 million, up 12% from the same period last year. At quarter’s end, backlog for the company was at $538 million, up 17%
Varian reported net earnings of $19.5 million versus $14 million in the same quarter last year. Sales for the quarter totaled $191 million, up 12% from the same period last year. At quarter’s end, backlog for the company was at $538 million, up 17% from the third quarter of last year. Oncology sales were up 15%, and x-ray sales were down 4%.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.